Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax, Inc. (NVAX) on Thursday announced preclinical data demonstrating that the company’s H5N1 bird flu vaccine candidate ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Meanwhile, Novavax also plans to use Warp Speed funds to ramp up COVID-19 vaccine manufacturing. The company has pledged to produce 100 million vaccine doses this year, and the partners could sign ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Novavax has reached a settlement with Gavi, the Vaccine Alliance (Gavi), ending arbitration tied to a 2021 advance purchase agreement (APA) around its prototype COVID-19 vaccine NVX-CoV2373.

Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday. The news sent company ...

If Novavax can turn the corner on its COVID-19 vaccine production, there will be much brighter days ahead for both investors and the billions globally who desperately need a vaccine.

Novavax says it will be able to deliver 100 million doses per month by the end of September and 150 million doses per month by the end of the year. The Novavax vaccine is what's known as a protein ...